Drug Profile

YOLT 203

Alternative Names: YOLT-203

Latest Information Update: 28 Nov 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator YolTech Therapeutics
Class Gene therapies; Uricosurics
Mechanism of Action Gene expression modulators; Glycolate oxidase expression inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Primary hyperoxaluria type 1
New Molecular Entity No

Highest Development Phases

Phase 0 Primary hyperoxaluria type 1
Preclinical Hyperuricaemia

Most Recent Events

19 Nov 2025 US FDA cleares the IND application for YOLT 203 for Primary hyperoxaluria type 1
19 Nov 2025 YolTech Therapeutics plans a pivotal trial for Primary hyperoxaluria type 1 in the US
28 Jul 2025 YOLT 203 receives Orphan Drug status for Primary hyperoxaluria type 1 in Europe

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com